Mutated IPK Enzyme Reconstructs Archaeal Mevalonate Pathway
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The isoprenoid pathway in archaea, known as 'The Lost Pathway,' is incomplete due to missing genes for phosphomevalonate kinase and diphosphomevalonate decarboxylase, hindering the biosynthesis of isopentenyl diphosphate (IPP), a crucial precursor for various isoprenoids essential for membrane stability, defense, and communication in organisms.
Innovation Solution
Identification and mutation of isopentenyl phosphate kinase (IPK) enzymes with specific amino acid substitutions, such as at Val62, Ala63, Tyr66, Leu67, Phe76, Met79, Phe83, Ile86, Ala89, Met90, Ile146, and Ile156, to enhance the phosphorylation of isopentenyl monophosphate to isopentenyl diphosphate, facilitating the reconstruction of the mevalonate pathway in archaea.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the conventional mevalonate pathway is used in archaea, then isoprenoid biosynthesis should occur, but the pathway is incomplete due to missing genes for phosphomevalonate kinase and diphosphomevalonate decarboxylase
Solution Approach 1:
The patent introduces isopentenyl phosphate kinase (IPK) as an intermediary enzyme that catalyzes the direct phosphorylation of isopentenyl monophosphate to isopentenyl diphosphate. This bypasses the missing pathway steps and restores functional completeness to the mevalonate pathway in archaea, solving the genetic deficiency without requiring the original missing enzymes.
Solution Approach 2:
The patent employs mutagenesis to alter specific amino acid residues in the IPK enzyme sequence (such as Val62, Ala63, Tyr66, Leu67, Phe76, Met79, Phe83, Ile86, Ala89, Met90, Ile146, and Ile156). These parameter changes in the enzyme's molecular structure optimize its catalytic activity and substrate binding, thereby enhancing the reconstruction of the mevalonate pathway.
2Productivity
If isopentenyl phosphate kinase (IPK) is used to phosphorylate isopentenyl monophosphate, then isopentenyl diphosphate is formed, but the formation rate is insufficient for high-level isoprenoid production
Solution Approach 1:
The patent applies directed mutagenesis to alter specific amino acid residues in the IPK enzyme sequence. These mutations are designed to optimize the enzyme's active site for enhanced catalytic activity and substrate binding. By changing parameters such as residue size, charge, and positioning at critical locations (Val62, Ala63, Tyr66, etc.), the enzyme's turnover number and catalytic efficiency are significantly improved, enabling high-level isoprenoid production.
Solution Approach 2:
The patent employs a feedback mechanism where the enzyme's activity is monitored and optimized through iterative mutagenesis and enzymatic assays. The mutations are selected and refined based on measured catalytic performance, creating a feedback loop that continuously improves the enzyme's productivity until optimal formation rates are achieved.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutated IPK enzymes significantly increase the formation rate of isoprenoid diphosphates, effectively bypassing the genetic deficiency and enabling the biosynthesis of essential isoprenoids in archaea, thereby supporting vital biological functions.
Implementation Method 1
contacting an isoprenoid monophosphate and a phosphate donor with a mutated isopentenyl phosphate kinase thereby forming an isoprenoid diphosphate
Data Source
AI summary
Provided herein are methods and compositions relating to the synthesis of isoprenoid diphosphates using a mutated isopentenyl phosphate kinase.